The U.S. FDA introduced Elsa, a generative AI tool designed to streamline operations like clinical protocol reviews and scientific evaluations. Commissioner Marty Makary announced the launch, highlighting that it was completed ahead of schedule and under budget through expert collaboration. Elsa aids in tasks such as summarizing adverse events and comparing packaging inserts while ensuring data privacy. The initiative comes as part of the FDA's broader strategy to integrate AI tools, with full implementation expected by June 30.
Today's rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers.
Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency.
Collection
[
|
...
]